Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation

Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro

Wenyue Hu, Claudio Sorrentino, Michael S. Denison, Kyle Kolaja, Mark R. Fielden

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of dioxin-like toxicity. As a result, induction of Cyp1a1 by pharmaceutical drug candidates or environmental contaminants raises significant concern in risk assessment. The current study evaluates the specificity of Cyp1a1 induction as a marker for AhR affinity and activation and provides context to assess the relevancy of AhR activation to risk assessment. In vivo experiments examined the expression of Cyp1a1 and other AhR-regulated genes in liver, kidney, and heart in response to 596 compounds. From this data set, a subset of 147 compounds was then evaluated for their ability to activate or bind to the AhR using a combination of gel shift, reporter gene, and competitive receptor binding assays. Whereas in vivo Cyp1a1 mRNA expression is a sensitive marker for AhR activation, it lacks specificity, because 81 (59%) of 137 compounds were found to significantly induce Cyp1a1 in vivo but were not verified to bind or activate the AhR in vitro. Combining in vivo and in vitro findings, we identified nine AhR agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, flutamide, and nimodipine. These drugs do not produce dioxin-like toxicity in rats or in humans. These data demonstrate that induction of Cyp1a1 is a nonspecific biomarker of direct AhR affinity and activation and lend further support to the hypothesis that Cyp1a1 induction and/or AhR activation is not synonymous with dioxin-like toxicity.

Original languageEnglish (US)
Pages (from-to)1475-1486
Number of pages12
JournalMolecular Pharmacology
Volume71
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Aryl Hydrocarbon Receptors
Biomarkers
Pharmaceutical Preparations
Dioxins
leflunomide
In Vitro Techniques
Flutamide
Nimodipine
Competitive Binding
United States Food and Drug Administration
Reporter Genes
Gels
Kidney

ASJC Scopus subject areas

  • Pharmacology

Cite this

Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation : Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. / Hu, Wenyue; Sorrentino, Claudio; Denison, Michael S.; Kolaja, Kyle; Fielden, Mark R.

In: Molecular Pharmacology, Vol. 71, No. 6, 06.2007, p. 1475-1486.

Research output: Contribution to journalArticle

Hu, Wenyue ; Sorrentino, Claudio ; Denison, Michael S. ; Kolaja, Kyle ; Fielden, Mark R. / Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation : Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. In: Molecular Pharmacology. 2007 ; Vol. 71, No. 6. pp. 1475-1486.
@article{f6d353a306f348f2a1d3a5c1da42a6bf,
title = "Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro",
abstract = "Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of dioxin-like toxicity. As a result, induction of Cyp1a1 by pharmaceutical drug candidates or environmental contaminants raises significant concern in risk assessment. The current study evaluates the specificity of Cyp1a1 induction as a marker for AhR affinity and activation and provides context to assess the relevancy of AhR activation to risk assessment. In vivo experiments examined the expression of Cyp1a1 and other AhR-regulated genes in liver, kidney, and heart in response to 596 compounds. From this data set, a subset of 147 compounds was then evaluated for their ability to activate or bind to the AhR using a combination of gel shift, reporter gene, and competitive receptor binding assays. Whereas in vivo Cyp1a1 mRNA expression is a sensitive marker for AhR activation, it lacks specificity, because 81 (59{\%}) of 137 compounds were found to significantly induce Cyp1a1 in vivo but were not verified to bind or activate the AhR in vitro. Combining in vivo and in vitro findings, we identified nine AhR agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, flutamide, and nimodipine. These drugs do not produce dioxin-like toxicity in rats or in humans. These data demonstrate that induction of Cyp1a1 is a nonspecific biomarker of direct AhR affinity and activation and lend further support to the hypothesis that Cyp1a1 induction and/or AhR activation is not synonymous with dioxin-like toxicity.",
author = "Wenyue Hu and Claudio Sorrentino and Denison, {Michael S.} and Kyle Kolaja and Fielden, {Mark R.}",
year = "2007",
month = "6",
doi = "10.1124/mol.106.032748",
language = "English (US)",
volume = "71",
pages = "1475--1486",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation

T2 - Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro

AU - Hu, Wenyue

AU - Sorrentino, Claudio

AU - Denison, Michael S.

AU - Kolaja, Kyle

AU - Fielden, Mark R.

PY - 2007/6

Y1 - 2007/6

N2 - Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of dioxin-like toxicity. As a result, induction of Cyp1a1 by pharmaceutical drug candidates or environmental contaminants raises significant concern in risk assessment. The current study evaluates the specificity of Cyp1a1 induction as a marker for AhR affinity and activation and provides context to assess the relevancy of AhR activation to risk assessment. In vivo experiments examined the expression of Cyp1a1 and other AhR-regulated genes in liver, kidney, and heart in response to 596 compounds. From this data set, a subset of 147 compounds was then evaluated for their ability to activate or bind to the AhR using a combination of gel shift, reporter gene, and competitive receptor binding assays. Whereas in vivo Cyp1a1 mRNA expression is a sensitive marker for AhR activation, it lacks specificity, because 81 (59%) of 137 compounds were found to significantly induce Cyp1a1 in vivo but were not verified to bind or activate the AhR in vitro. Combining in vivo and in vitro findings, we identified nine AhR agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, flutamide, and nimodipine. These drugs do not produce dioxin-like toxicity in rats or in humans. These data demonstrate that induction of Cyp1a1 is a nonspecific biomarker of direct AhR affinity and activation and lend further support to the hypothesis that Cyp1a1 induction and/or AhR activation is not synonymous with dioxin-like toxicity.

AB - Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of dioxin-like toxicity. As a result, induction of Cyp1a1 by pharmaceutical drug candidates or environmental contaminants raises significant concern in risk assessment. The current study evaluates the specificity of Cyp1a1 induction as a marker for AhR affinity and activation and provides context to assess the relevancy of AhR activation to risk assessment. In vivo experiments examined the expression of Cyp1a1 and other AhR-regulated genes in liver, kidney, and heart in response to 596 compounds. From this data set, a subset of 147 compounds was then evaluated for their ability to activate or bind to the AhR using a combination of gel shift, reporter gene, and competitive receptor binding assays. Whereas in vivo Cyp1a1 mRNA expression is a sensitive marker for AhR activation, it lacks specificity, because 81 (59%) of 137 compounds were found to significantly induce Cyp1a1 in vivo but were not verified to bind or activate the AhR in vitro. Combining in vivo and in vitro findings, we identified nine AhR agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, flutamide, and nimodipine. These drugs do not produce dioxin-like toxicity in rats or in humans. These data demonstrate that induction of Cyp1a1 is a nonspecific biomarker of direct AhR affinity and activation and lend further support to the hypothesis that Cyp1a1 induction and/or AhR activation is not synonymous with dioxin-like toxicity.

UR - http://www.scopus.com/inward/record.url?scp=34347327220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347327220&partnerID=8YFLogxK

U2 - 10.1124/mol.106.032748

DO - 10.1124/mol.106.032748

M3 - Article

VL - 71

SP - 1475

EP - 1486

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -